Similar Tracks
PFDD Workshop to Discuss Methodologic & Other Challenges Related to Patient Experience Data – Part 2
U.S. Food and Drug Administration
FDA Clinical Investigator Training Course (CITC) 2024 (Day 1 of 3)
U.S. Food and Drug Administration
PFDD Workshop to Discuss Methodologic & Other Challenges Related to Patient Experience Data – Part 1
U.S. Food and Drug Administration
FDA Perspectives on Biosimilar BLA-Manufacturing (28of33) Quality – Oct. 16-17, 2019
U.S. Food and Drug Administration
Regulatory Highlights for Biosimilars and Interchangeables (9of15) REdI – May 29-30, 2019
U.S. Food and Drug Administration
PFDD Workshop to Discuss Methodologic & Other Challenges Related to Patient Experience Data – Part 3
U.S. Food and Drug Administration
Overview of Post-approval Chemistry, Manufacture, and Controls (CMC) Changes to an NDA - REdI 2020
U.S. Food and Drug Administration
Postmarket Safety Surveillance: Tools, Methods, and Benefit-Risk Framework - Pharmacovigilance 2020
U.S. Food and Drug Administration
Clinicians Connect: Conversations w/ FDA's CMO on reducing cases of congenital syphilis & syphilis
U.S. Food and Drug Administration